Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease
Oral Ulceration Due to Behçet's Disease
About this trial
This is an interventional treatment trial for Oral Ulceration Due to Behçet's Disease focused on measuring Behcet Disease, Oral ulcers, oral ulceration
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with Behcet's disease as defined by the revised International Criteria for Behcet's Disease (ICBD2014). Patients with active oral ulcers. Patients free from any visible oral lesions other than the oral ulcers of BD. Patient who will agree to participate in the study and take the supplied interventions. Exclusion Criteria: Patients with history of a severe or chronic medical condition including congestive heart failure, malignancy and active infection including tuberculosis, hepatitis and human immunodeficiency virus. Patients who refuse to sign the informed consent.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Rebamipide mouthwash
Betamethasone mouthwash
Rebamipide mouthwash will be administered four times daily for one week or till healing
Betamethasone mouthwash of will be administered four times daily for one week or till healing